Related Experiment Videos
New possibilities for cancer therapy with advances in cancer immunology
1Department of Oncology, Faculty of Medicine, University of Alberta, Edmonton.
Abstract:
There has been progress over the last decade in addressing three questions: Are there cancer-associated antigens that could be targets for immunotherapy? Can the human immune system recognize cancer-associated antigens? Can an anti-cancer immune response affect cancer cells and lead to increased survival? Results from animal model studies have been interpreted by optimists as encouraging, and by pessimists as being irrelevant to human cancer. Earlier studies on "cancer vaccines" utilized heterogeneous cell extracts of cell components. Monoclonal antibodies have enabled identification of relevant cancer-associated antigens or epitopes, such as the ganglioside GM2, the carbohydrates TF and STn, and the peptide sequences of MUC-1. In parallel with research on immune adjuvants and measures designed to inhibit suppressor activity, these epitopes are being tested for their potential in the immunotherapy of solid tumors. It is clear that some of these cancer-associated epitopes are immunogenic in humans. Mixed responses may relate to cancer heterogeneity and may indicate the importance of multi-epitopic vaccines. Responses are encouraging, but are they relevant? Prolonged disease stability challenges us to re-think the goals of cancer therapy. Recent advances in the knowledge of the effect of cytokines on tumor antigen expression and the regulation of the immune response, coupled with advances in active specific immunotherapy, provide hope that biomodulation may become an important part of the therapy of solid tumors in the next century.
Insights
Cancer immunotherapy has advanced, identifying cancer antigens and demonstrating immune recognition and response. While challenges remain, these developments offer hope for future solid tumor treatments.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Progress in cancer immunotherapy over the last decade.
- Addressing key questions on cancer-associated antigens and immune response.
- Evaluating the relevance of animal model studies to human cancer.
Purpose of the Study:
- To review progress in cancer immunotherapy.
- To assess the potential of cancer-associated antigens as immunotherapy targets.
- To discuss the implications of recent advances for future cancer therapy.
Main Methods:
- Identification of cancer-associated antigens (e.g., GM2, TF, STn, MUC-1) using monoclonal antibodies.
- Testing of epitopes in immunotherapy for solid tumors.
- Research on immune adjuvants and suppressor activity inhibition.
Main Results:
- Some cancer-associated epitopes are immunogenic in humans.
- Cancer heterogeneity may necessitate multi-epitopic vaccines.
- Encouraging responses observed, with prolonged disease stability noted.
Conclusions:
- Cancer immunotherapy shows promise, with identified antigens and demonstrated immune responses.
- Further research into cytokines, immune regulation, and active specific immunotherapy is crucial.
- Biomodulation may become a significant component of solid tumor therapy in the future.